CoChat
Sign Up
Cited by 3Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and TreatmentsBotulinum Toxin and Related Neurological Disorders

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pharmacological Treatments of Tremor

Grimaldi, Giuliana, Manto, Mario·2013·Contemporary Clinical Neuroscience
DOI 10.1007/978-1-4614-4027-7_23
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1007/978-1-4614-4027-7_23

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 47

  1. Abboud H, Ahmed A, Fernandez HH. Essential tremor: Choosing the right management plan for your patient. Cleve Clin J Med. 2011;78(12):821–8. · DOI
  2. Bhidayasiri R. Differential diagnosis of common tremor syndromes. Postgrad Med J. 2005; 81:756–62. · DOI · Paper page
  3. Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol. 2003;250(6):693–7. · DOI
  4. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology. 2005;64:1078–80. · DOI
  5. Calzetti S, Sasso E, Negrotti A, Baratti M, Fava R. Effect of propranolol in head tremor: Quantitative study following single-dose and sustained drug administration. Clin Neuropharmacol. 1992;15(6):470–6. · DOI
  6. Ceravolo R, Salvetti S, Piccini P, Lucetti C, Gambaccini G, Bonuccelli U. Acute and chronic effects of clozapine in essential tremor. Mov Disord. 1999;14(3):468–72. · DOI
  7. Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: Findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol. 2008;31(2):97–103. · DOI
  8. Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammapathy. Neurology. 1990;40:212–4. · DOI
  9. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10(2):148–61. · DOI · Paper page
  10. Dyck PJ. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammapathy of unknown significance. Neurology. 1990;40:327–8. · DOI
  11. Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol. 2007;30(6):350–6. · DOI
  12. Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: A double blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985;48(9):911–5. · DOI
  13. Gates PC. Orthostatic tremor (shaky legs syndrome). Clin Exp Neurol. 1993;30:66–71.
  14. Gatto EM, Roca MC, Raina G, Micheli F. Low doses of topiramate are effective in essential tremor: A report of three cases. Clin Neuropharmacol. 2003;26(6):294–6. · DOI
  15. Gbadamosi J, Buhmann C, Moench A, Heesen C. Failure of ondansetron in treating cerebellar tremor in MS patients–an open-label pilot study. Acta Neurol Scand. 2001;104(5):308–11. · DOI
  16. Gonzalez-Alegre P, Kelkar P, Rodnitzky RL. Isolated high-frequency jaw tremor relieved by ­botulinum toxin injections. Mov Disord. 2006;21(7):1049–50. · DOI
  17. Gunal DI, Afşar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: Double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci. 2000; 21(5):315–7. · DOI
  18. Habib-ur-Rehman MRCP. Diagnosis and management of tremor. Arch Intern Med. 2000; 160(16):2438–44. · DOI
  19. Hammond ER, Kerr DA. Ethanol responsive tremor in a patient with multiple sclerosis. Arch Neurol. 2008;65(1):142–3. · DOI
  20. Handforth A, Martin FC. Pilot efficacy and tolerability: A randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord. 2004;19(10):1215–21. · DOI
  21. Henderson JM, Portmann L, Van Melle G, Haller E, Ghika JA. Propranolol as an adjunct therapy for hyperthyroid tremor. Eur Neurol. 1997;37(3):182–5. · DOI
  22. Iwata T, Nakai K, Sakamoto M, Dakeishi M, Satoh H, Murata K. Factors affecting hand tremor and postural sway in children. Environ Health Prev Med. 2006;11(1):17–23. · DOI
  23. Jiménez-Jiménez FJ, Garcia-Ruiz PJ, Cabrera-Valdivia F. Nicardipine versus propranolol in essential tumor. Acta Neurol (Napoli). 1994;16(4):184–8.
  24. Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A. Resting tremor in Parkinson disease: A negative predictor of levodopa-induced dyskinesia. Arch Neurol. 2011; 68(8):1037–9. · DOI
  25. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol. 1986;43(2):126–7. · DOI
  26. Koller WC, Herbster G. Adjuvant therapy of parkinsonian tremor. Arch Neurol. 1987; 44(9): 921–3. · DOI
  27. Liou LM, Shih PY. Successful treatment of rubral tremor by high-dose trihexyphenidyl: A case report. Kaohsiung J Med Sci. 2006;22(3):149–53. · DOI
  28. Manto M, Laute MA. A possible mechanism for the beneficial effect of ethanol in essential tremor. Eur J Neurol. 2008;15(7):697–705. · DOI
  29. Mehndiratta MM, Satyawani M, Gupta S, Khwaja GA. Clinical and surface EMG characteristics of valproate induced tremors. Electromyogr Clin Neurophysiol. 2005;45(3):177–82.
  30. Melmed C, Moros D, Rutman H. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Mov Disord. 2007;22(5):723–7. · DOI
  31. Metzer WS, Paige SR, Newton JE. Inefficacy of propranolol in attenuation of drug-induced ­parkinsonian tremor. Mov Disord. 1993;8(1):43–6. · DOI
  32. Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc. 1991;66(10):991–7. · DOI
  33. Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27(6):274–7. · DOI
  34. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF, Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672–7. · DOI
  35. Raj V, Landess JS, Martin PR. Oxcarbazepine use in essential tremor. Ann Pharmacother. 2006; 40(10):1876–9. · DOI
  36. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry. 1997;62(3):282–4. · DOI
  37. Rodrigues JP, Edwards DJ, Walters SE, Byrnes ML, Thickbroom GW, Stell R, Mastaglia FL. Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Mov Disord. 2006;21(7):900–5. · DOI
  38. Sadeghi R, Ondo WG. Pharmacological management of essential tremor. Drugs. 2010; 70(17): 2215–28. · DOI
  39. Sasso E, Perucca E, Fava R, Calzetti S. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis. Clin Neuropharmacol. 1990; 13(1): 67–76. · DOI
  40. Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: A review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25(12):1061–71. · DOI
  41. Serrano-Dueñas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003;10(1):29–33. · DOI
  42. Striano P, Coppola A, Vacca G, Zara F, Brescia Morra V, Orefice G, Striano S. Levetiracetam for cerebellar tremor in multiple sclerosis: An open-label pilot tolerability and efficacy study. J Neurol. 2006;253(6):762–6. · DOI
  43. Vidailhet M, Dupel C, Lehéricy S, Remy P, Dormont D, Serdaru M, Jedynak P, Veber H, Samson Y, Marsault C, Agid Y. Dopaminergic dysfunction in midbrain dystonia: Anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. Arch Neurol. 1999;56(8):982–9. · DOI
  44. Wills AJ, Brusa L, Wang HC, Brown P, Marsden CD. Levodopa may improve orthostatic tremor: Case report and trial of treatment. J Neurol Neurosurg Psychiatry. 1999;66(5):681–4. · DOI
  45. Yetimalar Y, Irtman G, Kurt T, Başoğlu M. Olanzapine versus propranolol in essential tremor. Clin Neurol Neurosurg. 2005;108(1):32–5. · DOI
  46. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey Jr RB, Okun MS, Sullivan KL, Weiner WJ. Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011; 77(19):1752–5. · DOI
  47. Zeuner KE, Molloy FM, Shoge RO, Goldstein SR, Wesley R, Hallett M. Effect of ethanol on the central oscillator in essential tremor. Mov Disord. 2003;18(11):1280–5. · DOI

Cited by

Sorted by citations

Metadata

Authors
Grimaldi, G., & Manto, M.
Affiliations
Université Libre de Bruxelles (BE)
Corresponding author
Grimaldi, Giuliana
ORCID
Manto, Mario
Venue
Contemporary Clinical Neuroscience
Publisher
Springer New York
Published
2012-07-14
Pages
419-429
ISSN
  • 2627-5341 (ISSN-L)
  • 2627-535X
DOI
10.1007/978-1-4614-4027-7_23
OpenAlex
W2340677557
Cited by
3
References
3
Citations by year
2024: 1 · 2022: 2
FWCI
0.00
Type
book chapter
Language
en
Open access
closed
Licence
Locations
  • Contemporary clinical neuroscience (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
Keywords
tremor, antitremor drugs, pharmacotherapy, movement disorders, tremor severity, quality of life, neurological disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review